FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3028773022> ?p ?o ?g. }

• W3028773022 endingPage "586" @default.
• W3028773022 startingPage "586" @default.
• W3028773022 abstract "586 Background: Taxane- and anthracycline-based neoadjuvant regimens have become a standard treatment for triple-negative breast cancer (TNBC). Previous studies have shown that adding carboplatin to neoadjuvant chemotherapy regimens significantly improved pCR rate in TNBC patients. The NeoCART study was designed to compare the efficacy and safety of docetaxel plus carboplatin with standard neoadjuvant chemotherapy in TNBC. Methods: NeoCART was designed as a multicenter, randomized controlled, open-label, phase 2 trial. The patients enrolled were at least 18 years old with previously untreated stage II-III (T1cN1-2 or T2-4N0-2) invasive TNBC who had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. All eligible patients were randomly assigned, in a 1:1 ratio, to the experimental arm (docetaxel (75 mg/m2) plus carboplatin (AUC 6) for six cycles) or the standard treatment arm (epirubicin 90 mg/m2 plus cyclophosphamide 600 mg/m2 four cycles, followed by docetaxel 100 mg/m2 for four cycles). The primary end point was the pCR rate (ypT0/is and ypN0). Secondary endpoints included event-free survival, frequency of breast-conserving surgery, and safety. Results: Between September 1, 2016, and December 31, 2019, 88 patients from 6 participating centers were included and randomized (44 patients to the DCb arm and 44 to the EC-D arm). In the primary end point analysis, 27 patients (61.4%, 95% CI 47.0 - 75.8) in the DCb group achieved a pCR compared with 17 patients (38·6%, 95% CI 24.3 - 53.0) in the EC-D group (odds ratio 2.52, 95% CI 2.4 - 43.1; p = 0.033). In different stage disease, the pCR rates of the DCb and the EC-D groups were 73.3% (22/30) vs 48.4% (15/31) in stage II (p = 0.046), and 35.7% (5/14) vs 15.4% (2/13) in stage III (p = 0.384). In patients with axillary lymph node involvement, the pCR rates were 45.8% (11/24) vs 30.8% (8/26) (p = 0.273); and 80.0% (16/20) vs 50.0% (9/18) with lymph node negative disease (p = 0.052). The frequency of breast-conserving surgery in the DCb and EC-D groups was 36.4% and 37.2%, respectively (p = 0·935). The grade 3/4 adverse events include anemia (4.5%), thrombocytopenia (2.3%), neutropenia (2.3%) and ALT/AST increased (2.3%) in the DCb group. Conclusions: Compared with the standard neoadjuvant regimen, docetaxel combined with carboplatin showed a higher pCR rate in TNBC. The higher pCR rate was more significant in patients with earlier disease stage and negative lymph node. Clinical trial information: NCT03154749 ." @default.
• W3028773022 created "2020-06-05" @default.
• W3028773022 creator A5003459470 @default.
• W3028773022 creator A5030691366 @default.
• W3028773022 creator A5033544481 @default.
• W3028773022 creator A5034083482 @default.
• W3028773022 creator A5034733312 @default.
• W3028773022 creator A5036761448 @default.
• W3028773022 creator A5039729883 @default.
• W3028773022 creator A5045873809 @default.
• W3028773022 creator A5046158460 @default.
• W3028773022 creator A5052217154 @default.
• W3028773022 creator A5052594077 @default.
• W3028773022 creator A5060120199 @default.
• W3028773022 creator A5068190515 @default.
• W3028773022 creator A5084018016 @default.
• W3028773022 creator A5088880132 @default.
• W3028773022 date "2020-05-20" @default.
• W3028773022 modified "2023-10-17" @default.
• W3028773022 title "Neoadjuvant docetaxel + carboplatin versus epirubicin+cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): Results from a multicenter, randomized controlled, open-label, phase II trial." @default.
• W3028773022 doi "https://doi.org/10.1200/jco.2020.38.15_suppl.586" @default.
• W3028773022 hasPublicationYear "2020" @default.
• W3028773022 type Work @default.
• W3028773022 sameAs 3028773022 @default.
• W3028773022 citedByCount "6" @default.
• W3028773022 countsByYear W30287730222021 @default.
• W3028773022 countsByYear W30287730222022 @default.
• W3028773022 crossrefType "journal-article" @default.
• W3028773022 hasAuthorship W3028773022A5003459470 @default.
• W3028773022 hasAuthorship W3028773022A5030691366 @default.
• W3028773022 hasAuthorship W3028773022A5033544481 @default.
• W3028773022 hasAuthorship W3028773022A5034083482 @default.
• W3028773022 hasAuthorship W3028773022A5034733312 @default.
• W3028773022 hasAuthorship W3028773022A5036761448 @default.
• W3028773022 hasAuthorship W3028773022A5039729883 @default.
• W3028773022 hasAuthorship W3028773022A5045873809 @default.
• W3028773022 hasAuthorship W3028773022A5046158460 @default.
• W3028773022 hasAuthorship W3028773022A5052217154 @default.
• W3028773022 hasAuthorship W3028773022A5052594077 @default.
• W3028773022 hasAuthorship W3028773022A5060120199 @default.
• W3028773022 hasAuthorship W3028773022A5068190515 @default.
• W3028773022 hasAuthorship W3028773022A5084018016 @default.
• W3028773022 hasAuthorship W3028773022A5088880132 @default.
• W3028773022 hasConcept C121608353 @default.
• W3028773022 hasConcept C126322002 @default.
• W3028773022 hasConcept C141071460 @default.
• W3028773022 hasConcept C143998085 @default.
• W3028773022 hasConcept C168563851 @default.
• W3028773022 hasConcept C203092338 @default.
• W3028773022 hasConcept C2776694085 @default.
• W3028773022 hasConcept C2776755627 @default.
• W3028773022 hasConcept C2776802502 @default.
• W3028773022 hasConcept C2777511904 @default.
• W3028773022 hasConcept C2778239845 @default.
• W3028773022 hasConcept C2778292576 @default.
• W3028773022 hasConcept C2780110267 @default.
• W3028773022 hasConcept C2780835546 @default.
• W3028773022 hasConcept C2781190966 @default.
• W3028773022 hasConcept C2781451048 @default.
• W3028773022 hasConcept C530470458 @default.
• W3028773022 hasConcept C71924100 @default.
• W3028773022 hasConceptScore W3028773022C121608353 @default.
• W3028773022 hasConceptScore W3028773022C126322002 @default.
• W3028773022 hasConceptScore W3028773022C141071460 @default.
• W3028773022 hasConceptScore W3028773022C143998085 @default.
• W3028773022 hasConceptScore W3028773022C168563851 @default.
• W3028773022 hasConceptScore W3028773022C203092338 @default.
• W3028773022 hasConceptScore W3028773022C2776694085 @default.
• W3028773022 hasConceptScore W3028773022C2776755627 @default.
• W3028773022 hasConceptScore W3028773022C2776802502 @default.
• W3028773022 hasConceptScore W3028773022C2777511904 @default.
• W3028773022 hasConceptScore W3028773022C2778239845 @default.
• W3028773022 hasConceptScore W3028773022C2778292576 @default.
• W3028773022 hasConceptScore W3028773022C2780110267 @default.
• W3028773022 hasConceptScore W3028773022C2780835546 @default.
• W3028773022 hasConceptScore W3028773022C2781190966 @default.
• W3028773022 hasConceptScore W3028773022C2781451048 @default.
• W3028773022 hasConceptScore W3028773022C530470458 @default.
• W3028773022 hasConceptScore W3028773022C71924100 @default.
• W3028773022 hasIssue "15_suppl" @default.
• W3028773022 hasLocation W30287730221 @default.
• W3028773022 hasOpenAccess W3028773022 @default.
• W3028773022 hasPrimaryLocation W30287730221 @default.
• W3028773022 hasRelatedWork W1565820605 @default.
• W3028773022 hasRelatedWork W1976715478 @default.
• W3028773022 hasRelatedWork W2331329572 @default.
• W3028773022 hasRelatedWork W2601506797 @default.
• W3028773022 hasRelatedWork W2727568273 @default.
• W3028773022 hasRelatedWork W2889964196 @default.
• W3028773022 hasRelatedWork W3028773022 @default.
• W3028773022 hasRelatedWork W3089122812 @default.
• W3028773022 hasRelatedWork W3204491303 @default.
• W3028773022 hasRelatedWork W4242015247 @default.
• W3028773022 hasVolume "38" @default.
• W3028773022 isParatext "false" @default.
• W3028773022 isRetracted "false" @default.
• W3028773022 magId "3028773022" @default.
• W3028773022 workType "article" @default.